Autolus Therapeutics plc announced that Andrew J. Oakley plans to retire from his position as chief financial officer with effect from March 31, 2022 and will concentrate on non-executive director roles. He currently serves on the Boards of Union Therapeutics A/S and Novaremed AG. Andrew will remain a senior advisor to Autolus until March 2023.

Dr. Lucinda Crabtree, senior vice president of finance at Autolus, will be appointed chief financial officer following his retirement. Dr. Lucinda Crabtree joined Autolus in January 2020 and currently serves as SVP Finance. Her prior roles included VP, Investor Relations and Corporate Communications and more recently she was heading up Business Strategy and Planning, which included oversight of the Financial Planning and Analytics function.

Lucinda oversaw Autolus' public offerings of American Depositary Shares in 2020 and 2021 and was a key contributor in closing the Blackstone transaction in November 2021.